Hepatocellular carcinomaJosep M. Llovet, Gregory J. Gores, Jessica Zucman‐Rossi et al.|Nature Reviews Disease Primers|2016Cited by 2.7k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, Vincent C. Tam et al.|NEJM Evidence|2022Cited by 1.4k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upArndt Vogel, Erika Martinelli, Andrés Cervantes et al.|Annals of Oncology|2018Cited by 1.1k
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomaBruno Sangro, Anthony B. El-Khoueiry, Ignacio Melero et al.|Journal of Hepatology|2020Cited by 421
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Ghassan K. Abou‐Alfa, Bruno Sangro, Stephen L. Chan et al.|Journal of Clinical Oncology|2022Cited by 398